These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 12033393)

  • 1. In vitro characterization and in vivo testosterone suppression of 6-month release poly(D,L-lactide) leuprolide microspheres.
    Woo BH; Na KH; Dani BA; Jiang G; Thanoo BC; DeLuca PP
    Pharm Res; 2002 Apr; 19(4):546-50. PubMed ID: 12033393
    [No Abstract]   [Full Text] [Related]  

  • 2. Preparation, characterization and in vivo evaluation of 120-day poly(D,L-lactide) leuprolide microspheres.
    Woo BH; Kostanski JW; Gebrekidan S; Dani BA; Thanoo BC; DeLuca PP
    J Control Release; 2001 Aug; 75(3):307-15. PubMed ID: 11489318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heterostereocomplexes prepared from d-PLA and l-PLA and leuprolide. II. Release of leuprolide.
    Slager J; Domb AJ
    Biomacromolecules; 2003; 4(5):1316-20. PubMed ID: 12959600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The application of microspheres from the copolymers of lactide and epsilon-caprolactone to the controlled release of steroids.
    Buntner B; Nowak M; Kasperczyk J; Ryba M; Grieb P; Walski M; Dobrzyñski P; Bero M
    J Control Release; 1998 Dec; 56(1-3):159-67. PubMed ID: 9801439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel approach for the intravenous delivery of leuprolide using core-cross-linked polymeric micelles.
    Hu Q; van Gaal EV; Brundel P; Ippel H; Hackeng T; Rijcken CJ; Storm G; Hennink WE; Prakash J
    J Control Release; 2015 May; 205():98-108. PubMed ID: 25583642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of Orntide microspheres in a rat animal model and correlation to in vitro release profiles.
    Kostanski JW; Dani BA; Reynolds GA; Bowers CY; DeLuca PP
    AAPS PharmSciTech; 2000 Oct; 1(4):E27. PubMed ID: 14727892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preparation of three-month depot injectable microspheres of leuprorelin acetate using biodegradable polymers.
    Okada H; Doken Y; Ogawa Y; Toguchi H
    Pharm Res; 1994 Aug; 11(8):1143-7. PubMed ID: 7971715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New long-acting injectable microspheres prepared by IVL-DrugFluidic™ system: 1-month and 3-month in vivo drug delivery of leuprolide.
    Kim M; Kim JH; Kim S; Maharjan R; Kim NA; Jeong SH
    Int J Pharm; 2022 Jun; 622():121875. PubMed ID: 35636628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustained suppression of the pituitary-gonadal axis by leuprorelin three-month depot microspheres in rats and dogs.
    Okada H; Doken Y; Ogawa Y; Toguchi H
    Pharm Res; 1994 Aug; 11(8):1199-203. PubMed ID: 7971724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hetero-stereocomplexes of D-poly(lactic acid) and the LHRH analogue leuprolide. Application in controlled release.
    Slager J; Domb AJ
    Eur J Pharm Biopharm; 2004 Nov; 58(3):461-9. PubMed ID: 15451519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thiolated chitosan nanoparticles for the nasal administration of leuprolide: bioavailability and pharmacokinetic characterization.
    Shahnaz G; Vetter A; Barthelmes J; Rahmat D; Laffleur F; Iqbal J; Perera G; Schlocker W; Dünnhaput S; Augustijns P; Bernkop-Schnürch A
    Int J Pharm; 2012 May; 428(1-2):164-70. PubMed ID: 22421322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An eight-month clinical study of LA-2575 30.0 mg: a new 4-month, subcutaneous delivery system for leuprolide acetate in the treatment of prostate cancer.
    Sartor O; Dineen MK; Perez-Marreno R; Chu FM; Carron GJ; Tyler RC
    Urology; 2003 Aug; 62(2):319-23. PubMed ID: 12893343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase-sensitive polymer-based controlled delivery systems of leuprolide acetate: in vitro release, biocompatibility, and in vivo absorption in rabbits.
    Singh S; Singh J
    Int J Pharm; 2007 Jan; 328(1):42-8. PubMed ID: 16959451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of a cage implant system for assessing in vivo performance of long-acting release microspheres.
    Doty AC; Hirota K; Olsen KF; Sakamoto N; Ackermann R; Feng MR; Wang Y; Choi S; Qu W; Schwendeman A; Schwendeman SP
    Biomaterials; 2016 Dec; 109():88-96. PubMed ID: 27693924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and in vivo evaluation of a new oral nanoparticulate dosage form for leuprolide based on polyacrylic acid.
    Iqbal J; Vigl C; Moser G; Gasteiger M; Perera G; Bernkop-Schnürch A
    Drug Deliv; 2011 Aug; 18(6):432-40. PubMed ID: 21557716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Feasibility of poly (ϵ-caprolactone-co-DL-lactide) as a biodegradable material for in situ forming implants: evaluation of drug release and in vivo degradation.
    Zhang X; Zhang C; Zhang W; Meng S; Liu D; Wang P; Guo J; Li J; Guan Y; Yang D
    Drug Dev Ind Pharm; 2015 Feb; 41(2):342-52. PubMed ID: 24320881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Preparation of cyclosporine A loaded mPEG-PLGA copolymer micelles and study its pharmacokinetics in rats].
    Yao DG; Sun KX; Mu HJ; Zhou FM; Chen HH; Liu LJ; Liang N
    Yao Xue Xue Bao; 2009 Dec; 44(12):1410-5. PubMed ID: 21351479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decrease of genital organ weights and plasma testosterone levels in rats following oral administration of leuprolide microemulsion.
    Zheng JY; Fulu MY
    Int J Pharm; 2006 Jan; 307(2):209-15. PubMed ID: 16300912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of Recombinant Human Growth Hormone (rhGH) sustained-release microspheres by a low temperature aqueous phase/aqueous phase emulsion method.
    Kang J; Wu F; Cai Y; Xu M; He M; Yuan W
    Eur J Pharm Sci; 2014 Oct; 62():141-7. PubMed ID: 24907681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In situ forming microparticle system for controlled delivery of leuprolide acetate: influence of the formulation and processing parameters.
    Luan X; Bodmeier R
    Eur J Pharm Sci; 2006 Feb; 27(2-3):143-9. PubMed ID: 16243496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.